| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Canopy Growth Corporation Common Shares$0.97
+0.02 (+2.49%)
F 17Pipeline Score Tools & Services · Commercial
Market Cap
474.70 M
EPS
-1.34
P/E Ratio
-0.79 $
Value Trade
6.16 M
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Burn Trend
Insufficient_dataSEC Filing
Jun 15, 2026
Overview
Volume
2.64 M
52 Week Range
0.84 - 2.38
% held by Insiders
0.38 %
% held by Institutions
7.62 %
Enterprise Value
386.42 M
Total Shares
377.86 M
Short %
5.38 %
Float Shares
377.86 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F17
Pipeline Score $29M
Pipeline ValueValuation Signal
2
Drugs Scored0.1x
rNPV / MCap Top 16%
Micro Cap (rank 761 of 905)
Percentile RankCanopy Growth Corporation Common Shares has significant pipeline risk (17/100), with $234M risk-adjusted pipeline value, led by CHI-554 in Anxiety (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CHI-554 Small molecule | Anxiety | Phase 2 | NCT04577612 | 12% | $137M | COMPLETED | 84 | - | - | May 1, 2021 | - | Jun 2, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CGC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
CGC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CGC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CGC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CGC Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
CGC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-CGC
Jun 15, 2026Canopy Growth Reports Fourth Quarter and Fiscal Year 2026 Financial Results; Delivers Q4 FY2026 Net Revenue Growth of 27% in Canada Medical and 68% in International Markets Cannabis
Canopy Growth has reported its financial results for the fourth quarter and fiscal year 2026, highlighting a net revenue growth of 27% in Canada’s medical cannabis sector and 68% growth in international markets. The report reflects the company's ongoing efforts to expand its market presence and improve financial performance. Further details on operational strategies and future outlook were not disclosed.
Read more →-CGC
Jun 8, 2026Canopy Growth Announces Claybourne’s Frosted Flyers Wins ‘Best Infused Pre-Roll' at 2026 Grow Up Awards
Canopy Growth Corporation announced that its Claybourne's Frosted Flyers Variety Pack won the Best Infused Pre-Roll award at the 2026 Grow Up Awards. The company is expanding its Frosted Flyers lineup with new variety packs to cater to consumer preferences. This expansion aims to enhance market share and provide more options for consumers this summer.
Read more →-CGC
May 29, 2026Canopy Growth Relaunches Tweed Brand in Germany with New MTL Cannabis Strain Lineup, Marking First International Release following Acquisition
Canopy Growth has announced the relaunch of its Tweed brand in Germany, introducing a new lineup of MTL cannabis strains. This marks the company's first international release following its recent acquisition. The move is seen as a strategic expansion into the European market, aiming to enhance brand visibility and product offerings.
Read more →-CGC
May 7, 2026Canopy Growth and Spectrum Therapeutics Expand Medical Portfolio with New 30 and 90-Pack Softgels and Enhanced Dosing Options
Canopy Growth Corporation and Spectrum Therapeutics have expanded their Minor Cannabinoid softgel lineup by introducing new 30 and 90-pack formats along with enhanced dosing options. This expansion aims to improve patient access and reflects the companies' commitment to addressing patient needs. The new formulations are designed to support both daytime and nighttime use, enhancing convenience and affordability for patients.
Read more →-CGC
Apr 23, 2026‘There’s a Tweed for That’: Canopy Growth Announces Tweed Brand Summer Campaign
Canopy Growth Corporation has announced a refresh of its Tweed brand, launching a national summer campaign titled 'There’s a Tweed for That.' The campaign aims to enhance consumer experience by introducing new window bags for Tweed's flower SKUs, allowing customers to see the product before purchase. This initiative is expected to strengthen Tweed's position in the Canadian cannabis market.
Read more →Competitive Position
How CGC ranks across every disease it competes inCompetitive Position is a premium feature
See how CGC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial